Overview
Glycemic Excursions in Type 2 Diabetic Patients With Vildagliptin and Metformin Versus Vildagliptin and Glimepiride
Status:
Completed
Completed
Trial end date:
2016-02-22
2016-02-22
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study was to compare the effect of a fixed dose combination of vildagliptin plus metformin versus combination therapy of glimepiride plus metformin in glycemic variability in patients with type 2 diabetes who have not achieved adequate control of their disease prior to treatment with metformin monotherapy in optimal doses.Phase:
Phase 4Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Novartis PharmaceuticalsTreatments:
Glimepiride
Metformin
Vildagliptin
Criteria
Key Inclusion Criteria:- HbA1c between 8%-10.5% in stable metformin dose (>1500 mg/day), four weeks prior visit
1
Key Exclusion Criteria:
- Use of other antidiabetic oral therapy during the last 3 months (sulphonylurea,
glitazones, GLP-1 analogues, DPP-4 inhibitors), except metformin